Retatrutide Triple Hormone Receptor Agonist: Mechanism, Evidence, and UK Status
Retatrutide, the triple hormone receptor agonist peptide for obesity, shows promising Phase 2 results. Learn how it works, its safety profile, UK regulatory status, and how to discuss it with your GP.